FDA Peptide Advisory Committee Vote, July 2026: Every Tally, and What Changes

On 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee (PCAC) met at the agency's White Oak campus in Silver Spring, Maryland, and voted on whether seven peptides should be added to the list of bulk drug substances that 503A compounding pharmacies may use. Six passed: BPC-157, KPV, TB-500 and MOTS-c on the Thursday, Semax and Epitalon on the Friday. One failed: emideltide, better known to researchers as DSIP, went down 6 to 7. Career FDA scientists had recommended against every one of the seven.

The votes are advisory. Nothing changed on 25 July for a compounding pharmacy, a clinic or a researcher, and nothing has changed as of the first week of September 2026. What changed is the direction of travel. This page sets out what was voted on, the exact tallies, what a 503A bulks-list nomination actually is, why the vote is non-binding, and how the same peptides went from prohibited in September 2023 to recommended in July 2026.

The seven votes, with tallies

The FDA's meeting page split the substances across two days. Thursday 23 July covered BPC-157 (nominated for ulcerative colitis), KPV (wound healing and inflammatory conditions), TB-500 (wound healing) and MOTS-c (obesity and osteoporosis). Friday 24 July covered emideltide (opioid withdrawal, chronic insomnia and narcolepsy), Semax (cerebral ischaemia, migraine and trigeminal neuralgia) and Epitalon (insomnia). Each was nominated as the free base or acetate salt.

The tallies below are taken from the McDermott Will & Emery summary of the two-day meeting, cross-checked against AJMC, PharmExec and STAT reporting. The FDA meeting page itself lists the agenda and briefing materials but does not publish the vote counts.

Two things stand out in the numbers. Every margin was narrow: the widest was 7 to 4 for Epitalon, and the four Thursday votes all passed by two. And the committee was split in a consistent way, with the same bloc voting yes on each compound. STAT reported that eight of the committee's 14 members were recent appointments and that six of them run peptide clinics, a point Paul Knoepfler of UC Davis raised publicly: "Many members who voted yes could gain from allowing BPC-157. How is that acceptable?" The Bureau reports that as a criticism that was made, not as a finding.

What FDA's own scientists said

The agency's review staff recommended against all seven. The stated reasons were the ones you would expect from a drug reviewer: limited or no human data, unresolved questions about safety, and in several cases an existing FDA-approved treatment for the nominated condition. On BPC-157 the staff briefing pointed to "limited evidence about the peptide's effectiveness" and to approved therapies for ulcerative colitis. On KPV, staff said none of the studies they found were in humans.

The more unusual objection was about identity. Russell Wesdyk of the FDA told the committee the agency had "never faced a problem of, 'What is it?'" The concern was that for some of these peptides there is no universally accepted chemical specification to compound against, which is a problem for a pharmacy that has to buy a bulk substance from a supplier and verify it. Josh Mailman, a committee member, put the same worry from the other side of the table: "I'm voting on something here, but I don't know what that something is. It's like a black box."

On the Friday, Mary Thanh Hai, director of the Office of New Drugs, drew the line between the grey market and the compounding pathway: in the grey market, she said, evidence of safety and efficacy "is not a requirement to be sent to us." Committee member Asare Christian, who founded a wellness clinic, said the discussion kept drifting into dosing, efficacy and safety, "and it doesn't look like that's what we've been asked to do."

What a 503A bulks-list nomination is

Section 503A of the Federal Food, Drug and Cosmetic Act lets a licensed pharmacist compound a drug for an individual patient on a prescription without the drug going through FDA approval. One of the conditions is that any bulk drug substance used must either be the subject of a USP or NF monograph, be a component of an FDA-approved drug, or appear on a list of bulk drug substances the FDA has developed through rulemaking. That list is the "503A bulks list".

None of the seven peptides has a USP monograph, none is a component of an approved drug, and none is on the list. That is why they cannot be legally compounded today. The route onto the list is nomination, FDA review, a PCAC meeting where the committee votes on the agency's questions, and then notice-and-comment rulemaking in which the FDA publishes a proposed rule, takes public comments, and issues a final rule.

While the list was being built the FDA ran an interim system with three categories. Category 1 substances were those with adequate support and no identified safety concern; the FDA exercised enforcement discretion and allowed compounding with them while rulemaking continued. Category 2 substances were those where the agency had identified significant safety risks, and it would not exercise discretion. Category 3 substances lacked enough information to assess. In 2025 the FDA said it would no longer categorise newly nominated substances, though existing Category 1 listings keep their interim status. The DSIP guide and MOTS-c guide cover the individual compounds.

Why the vote is non-binding, and the precedent for ignoring it

PCAC advises. The statute gives the decision to the FDA, and the agency has to act through rulemaking rather than by adopting the committee's recommendation on the day. STAT noted that it is unusual for the FDA to go against a PCAC recommendation, but that it has happened at least once before. The current leadership adds a variable: HHS Secretary Robert F. Kennedy Jr. has described himself as "a big fan" of peptides, and STAT reported that he or acting FDA Commissioner Kyle Diamantas could overrule the career staff position. So the political weight is on the side of the yes votes even where the scientific staff were not.

What a positive vote does not do is create a legal basis for compounding right now. McDermott's analysis is blunt on this: peptides recommended by PCAC "do not technically meet any of the three categories of permissible compounding" until they are added to the list by rule. A pharmacy that starts compounding BPC-157 in September 2026 on the strength of the July vote is compounding with a substance that is not on the list, and the FDA's stated position on that has not changed.

The Category 2 history: how these peptides got here

In September 2023 the FDA moved more than a dozen peptides into Category 2 of the interim 503A list, citing "significant safety concerns" that included immunogenicity risk, impurity profiles and limited human clinical data. BPC-157, TB-500, MOTS-c, Semax, Epitalon, KPV, emideltide and others went onto that list. The practical effect, as the Hyman Phelps FDA Law Blog notes, was smaller than it sounded, because these peptides were never in Category 1 and so could not have been legally compounded in the first place. What the 2023 action did was close the door that some compounders had been treating as ajar, and it triggered a wave of clinics dropping BPC-157 and TB-500 through late 2023 and 2024.

The turn came in the spring of 2026. On 15 April 2026 Secretary Kennedy confirmed that twelve peptides were being removed from Category 2: BPC-157, TB-500, MOTS-c, injectable GHK-Cu, Melanotan II, Semax, PEG-MGF, emideltide, Epitalon, KPV, cathelicidin LL-37 and dihexa acetate. On 16 April the FDA published a Federal Register notice announcing the July PCAC meeting for seven of them, and said the remaining five (GHK-Cu, Melanotan II, LL-37, dihexa and PEG-MGF) would be reviewed by the end of February 2027.

Removal from Category 2 did not put anything into Category 1. It simply took away the explicit "do not compound" designation and sent the substances to the committee. That is the state they are in now: no longer listed as unsafe, not yet listed as permitted.

What changes for researchers, and what does not

For a researcher buying lyophilised BPC-157 or TB-500 from a research-compound vendor, the July vote changes nothing about the product, the law or the FDA's enforcement posture. Research-use-only sales fall under a different part of the statute from compounding, and the FDA's warning-letter programme against online peptide sellers continued through the summer: letters dated 24 August 2026 went to five vendors and were posted on 1 September, a week after the vote. The vendor shutdown tracker lists them.

What the vote may change over the next year or two is supply on the clinical side. If BPC-157 reaches the bulks list, a 503A pharmacy will be able to compound it on prescription from a supplier that meets USP standards, and that supplier will have to resolve exactly the identity questions the FDA raised. For the research market the likely effect is indirect: a pharmacy-grade specification for BPC-157 acetate would give vendors and testing labs a reference to test against, which the peptide testing guide currently has to work around.

For a researcher planning a protocol, the practical question is the same as it was in June. Read the batch COA, reconstitute correctly (the BPC-157 dosage calculator does the unit arithmetic), and treat the compound as what it is: an unapproved research substance whose regulatory status is in motion. The BPC-157 guide and TB-500 guide cover the published data for the two most-searched of the seven.

What changes for compounding pharmacies, and the timeline

For a 503A pharmacy, the July vote is a signal to prepare rather than a licence to act. The three-step sequence PharmExec described is: removal from Category 2 (done, April 2026), a positive committee recommendation (done for six of seven, July 2026), and notice-and-comment rulemaking to place each substance on the list. PharmExec put the rulemaking at typically eight to twelve months for legal clarity; McDermott expects completion "in 2027" or a multi-year process; the FDA Law Blog says notice-and-comment rulemaking "can take more than a year." Nobody the Bureau found expects a final rule in 2026.

The FDA has also not addressed the 503B outsourcing-facility side, which runs on a separate bulks list with its own nomination process. And the five peptides deferred to February 2027, including injectable GHK-Cu, are a further year behind. Anyone reading the July headlines as "peptides are legal now" has misread them. The accurate reading is that six peptides moved one step along a four-step path, that the last step is the slowest, and that the agency's own scientists are on record against all six.

The Bureau will update the table above when the FDA publishes a proposed rule for any of the seven. Nothing here is medical advice; these are research compounds and the Bureau does not advise anyone on using them.

Frequently Asked Questions

Which peptides did the FDA committee vote for in July 2026?

Six of seven. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6 with one abstention for BPC-157, KPV and TB-500, and 7 to 5 with two abstentions for MOTS-c. On 24 July it voted 8 to 5 for Semax and 7 to 4 for Epitalon. Emideltide, sold to researchers as DSIP, failed 6 to 7 with one abstention. FDA review staff had recommended against all seven. The tallies come from law-firm and trade-press summaries; the FDA's meeting page posts materials but not vote counts.

Is BPC-157 legal to compound now?

No. A positive PCAC vote is a recommendation, not a rule. BPC-157 is not on the 503A bulks list, has no USP monograph and is not a component of an approved drug, so a 503A pharmacy still has no legal basis to compound it. The FDA must publish a proposed rule, take public comment and issue a final rule. Estimates the Bureau found range from eight to twelve months to more than a year, with completion expected in 2027 at the earliest. Removal from Category 2 in April 2026 lifted the explicit prohibition but did not grant permission.

What does removal from Category 2 mean?

Category 2 was the FDA's interim label for nominated bulk substances with identified safety concerns, where the agency would not exercise enforcement discretion. In September 2023 it placed BPC-157, TB-500, MOTS-c, Semax, Epitalon, KPV and others there. On 15 April 2026 twelve peptides were removed and sent to the advisory committee. Removal does not place a substance in Category 1 and does not authorise compounding; it means the FDA is no longer designating it as unsafe for compounding while it reconsiders. Until a final rule adds it to the list, the legal position is unchanged.

Why did FDA scientists oppose the peptides?

The review staff cited limited or absent human data, unresolved safety questions and, for several nominations, approved alternatives for the same condition. On KPV, staff said none of the studies they found were in humans. A separate objection concerned identity: FDA official Russell Wesdyk said the agency had never before faced the question of what a nominated substance actually is, because there is no accepted chemical specification for some of these peptides. Committee member Josh Mailman said he felt he was voting on a black box. The committee voted yes on six regardless.

Does the vote affect research-use-only peptide vendors?

Not directly. Compounding under section 503A and the sale of research compounds are governed by different provisions, and the FDA's enforcement against online sellers continued after the vote: warning letters dated 24 August 2026 to five vendors were posted on 1 September, citing sales of unapproved new drugs despite research-only labelling. What may change over time is the existence of a pharmacy-grade specification for compounds like BPC-157 acetate, which would give testing labs a reference standard. For now, the research market's legal exposure and product quality questions are the same as before July.

When will the FDA make a final decision?

No date has been set. The next step is a proposed rule for each substance, followed by a comment period and a final rule. PharmExec reported eight to twelve months as typical for legal clarity; McDermott Will and Emery expects completion in 2027 or a multi-year process; the FDA Law Blog says notice-and-comment rulemaking can take more than a year. Five further peptides, including injectable GHK-Cu and Melanotan II, are due before the committee by the end of February 2027. The Bureau will update this page when a proposed rule is published.

Research use only. The compounds discussed are sold as research chemicals and are not approved for human use. Nothing here is medical advice.